Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, announced the final close of its oversubscribed $105 million Series C funding. The round was led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, with participation from new investors New Vintage, Apollo Health Ventures and Benvolio Group, among others.